← Leaderboards
Gordon Alton
Visionary Pharmaceuticals, Inc.
$1,278,934
Attributed
$2,025,252
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $824.7K · FY2013–17$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,025,252 · 3
By mechanism
R44$1,492,636 · 1
R43$532,616 · 2
Top collaborators
- Jim Zapf2 shared
Most similar at Visionary Pharmaceuticals, Inc.
Same institution · by research overlap
- Jim Zapf$1,732,547
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadBiological MarkersPharmacologic SubstancePropertyIn VitroDrug KineticsIn VivoPharmaceutical ChemistrySeriesCellsBaseB-LymphocytesAdverse EventAttenuatedBiological AvailabilityAnimal ModelDosageBioavailableCell LineageAnimal EfficacyCellular BiologyChemical PropertyClinical TrialsAdverse Effects
Grant awards (4)
Discovery of Novel Therapeutics for Glioblastoma$300,000
R43 · FY2017 · CA · contact PI
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$667,910
R44 · FY2015 · DK · contact PI
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$824,726
R44 · FY2014 · DK · contact PI
Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD$232,616
R43 · FY2013 · DK · contact PI